Volume 17, Number 10—October 2011
Yellow Fever Virus Vaccine–associated Deaths in Young Women1
- Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, Fever and multisystem organ failure associated with 17D–204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98–104.
- Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91–7.
- Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D–204 yellow fever vaccine. Lancet. 2001;358:121–2.
- Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–82.
- Barwick R. History of thymoma and yellow fever vaccination. Lancet. 2004;364:936.
- Vasconcelos PF, Bryant JE, da Rosa TP, Tesh RB, Rodrigues SG, Barrett AD. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis. 2004;10:1578–84.
- Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine–associated viscerotropic disease. South Med J. 2005;98:653–6.
- Doblas A, Domingo C, Bae HG, Bohorquez CL, de Ory F, Niedrig M, Yellow fever vaccine–associated viscerotropic disease and death in Spain. J Clin Virol. 2006;36:156–8.
- Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, Lanciotti R, Fatal multiorgan failure due to yellow fever vaccine–associated viscerotropic disease. Vaccine. 2007;25:8480–5.
- Whittembury A, Ramirez G, Hernandez H, Ropero AM, Waterman S, Ticona M, Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27:5974–81.
- Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines, 5th ed. Philadelphia: Saunders; 2008. p. 959–1055.
- Struchiner CJ, Luz PM, Dourado I, Sato HK, Aguiar SG, Ribeiro JG, Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect. 2004;132:939–46.
- Engel AR, Vasconcelos PF, McArthur MA, Barrett AD. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine. 2006;24:2803–9.
- Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol. 2010;17:118–26.
- Sutton AL, Smithwick EM, Seligman SJ, Kim DS. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med. 1974;56:545–53.
1Data previously presented at a National Institutes of Health–supported Northeast Biodefense Center conference, New Paltz, New York, USA, November 2, 2010.
Page created: September 23, 2011
Page updated: September 23, 2011
Page reviewed: September 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.